Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H28N3O4S2.Na |
| Molecular Weight | 497.606 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CCCCOC(=O)[N-]S(=O)(=O)C1=C(C=C(CC(C)C)S1)C2=CC=C(CN3C=CN=C3)C=C2
InChI
InChIKey=ZUHAJKQDALIGJV-UHFFFAOYSA-M
InChI=1S/C23H29N3O4S2.Na/c1-4-5-12-30-23(27)25-32(28,29)22-21(14-20(31-22)13-17(2)3)19-8-6-18(7-9-19)15-26-11-10-24-16-26;/h6-11,14,16-17H,4-5,12-13,15H2,1-3H3,(H,25,27);/q;+1/p-1
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25560767 |
https://www.ncbi.nlm.nih.gov/pubmed/19029468
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25560767 |
https://www.ncbi.nlm.nih.gov/pubmed/19029468
Compound M24 is a selective angiotensin II AT2 receptor agonist with a Ki value of 0.4 nM for the AT2 receptor. Compound enhances in vivo duodenal alkaline secretion in Sprague-Dawley rats, and lowers the mean arterial blood pressure in anesthetized, spontaneously hypertensive rats. In a mouse model of atherosclerosis, plaque size and stability were improved in ApoE‐/‐ mice treated with M24. Treatment with M24 resulted in decrease in scar size and reduction in markers of inflammation in a rat model of myocardial infaction.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Compound 21, a selective agonist of angiotensin AT2 receptors, prevents endothelial inflammation and leukocyte adhesion in vitro and in vivo. | 2016-02 |
|
| Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? | 2008-12-09 |
|
| Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. | 2004-11-18 |
Patents
Sample Use Guides
The in vivo experiments were performed on anaesthetized nonfasted male Sprague-Dawley rats and spontaneously hypertensive rats (SHR). Compound M24 was administered intravenously at 0.003-0.3 mg/kg h. Oral PK study on rats have demonstrated absolute bioavailability of 20-30%. In the model of miocardial infarction rats were treated with M24 intraperitoneally at 0.01-0.3 mg/kg.
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
550816
Created by
admin on Tue Apr 01 20:41:27 GMT 2025 , Edited by admin on Tue Apr 01 20:41:27 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Y151F1Q61I
Created by
admin on Tue Apr 01 20:41:27 GMT 2025 , Edited by admin on Tue Apr 01 20:41:27 GMT 2025
|
PRIMARY | |||
|
126961847
Created by
admin on Tue Apr 01 20:41:27 GMT 2025 , Edited by admin on Tue Apr 01 20:41:27 GMT 2025
|
PRIMARY | |||
|
300000001701
Created by
admin on Tue Apr 01 20:41:27 GMT 2025 , Edited by admin on Tue Apr 01 20:41:27 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
